OLYMPUS TECHNOZONE Vol.54 2002-08

INDEX | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |

Research in new fields accelerating in response to increasing public expectations

Karaki: 
The very concept of a DNA computer is new, and our involvement in this field is thanks to Dr. Suyama. I am constantly aware that such opportunities are very rare.

Makino: 
The development of the endoscope may have followed a similar pattern to our present project. Physicians and Olympus engineers worked together with a common goal in a previously unknown field.

I wonder if the DNA computer will become another "Project X"? Perhaps we haven't tried hard enough. We need more drama and excitement.

Karaki: 
Yet the excitement triggered by our announcement is a sign that people are eager to see something really new.

Makino: 
There was more coverage in the general magazine than trade journals. The announcement was even covered by TV news programs.

Karaki: 
There was also coverage in technical journals, including those specializing in semiconductors and information technology. I am convinced that DNA computing encapsulates future expectations in many fields.

Suyama: 
One reason for this is Olympus's excellent reputation. The public sees you as an organization that can be trusted. DNA computing is still a very nebulous field that requires the efforts of trustworthy people.

Karaki: 
Nebulous, isn't it?

Suyama: 
At the outset everyone wonders what use their research will be. Research that involves a lot of uncertainties should be carried out by reliable people. It is important to have reliable people meeting the challenges of new and unknown research endeavors.

Karaki: 
Our company is serious, prudent, and conservative. People see us as an organization that would not even make a risky attempt. With DNA computing, however, we've taken a bold step forward.

Suyama: 
I think that the establishment of a venture business has really made a difference.

Karaki: 
Indeed. I think we moved extremely quickly from the initial proposal to the establishment of NovusGene.

Makino: 
NovusGene is now in its second year. Thanks to the announcement of the DNA computer, its name is now widely known. From the outset we stressed that biomolecular computing would be NovusGene's core technology, so the announcement came at an opportune time. I wanted the announcement to be made one year after the establishment of NovusGene, so that it would not be forgotten.

Quantum computing has yet to produce anything tangible. They say quantum computers will be able to carry out large-scale factor analysis, and argue that this will lead to the deciphering of complex codes, but I don't know.

Suyama: 
That is just theoretically possible, but it has not actually been achieved. In contrast, the DNA computer has already reached the stage at which actual problems can be solved, so we are closer to the practical application stage. However, researchers specializing in computer science generally have little experience in biotechnology, so they tend to focus on quantum computing, which is closer to conventional electronic computing.

Moreover, in terms of achievements so far, the need for DNA computers is far greater. It seems obvious that quantum computers will replace electronic computers in the future. That's because the direction of technological innovation is the same. However, the problems that are about to be solved by DNA computers represent an entirely new direction. For this reason, I believe in the potential of DNA computers.


>>Click here for the further information of DNA Computer
INDEX | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
previous

Top of this page




Start of contact us and terms of use menus


Copyright OLYMPUS CORPORATION All Rights Reserved.